CellPoint (a Galapagos company) believes the future of cell therapy is at the point-of-care, near the patient. The company is developing point-of-care candidate CAR-T therapies that could potentially solve unmet needs of patients with hematological cancer and offer the potential for more rapidly available, affordable treatments. Phase I/II clinical trials with CellPoint candidate CAR-T constructs are currently ongoing in various haematological malignancies.